Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Matthias Holdhoff, MD
National Cancer Institute (NCI)
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uab Comprehensive Cancer Center
Birmingham, Alabama, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- Dana-Farber/harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Henry Ford Hospital
Detroit, Michigan, United States
- Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
- Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
- Abrams Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Dec 2017
- Primary completion
- 3 Jun 2022
- Completion
- 24 Aug 2022
- Last update posted
- 24 Jun 2024
- Registered enrollment
- 26
- Registry id
- NCT03250299
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.